Case Report: A Case of Acute Cellular Rejection Due to Atopic Dermatitis Exacerbation 3 Years After Heart Transplantation.
acute cellular rejection
atopic dermatitis
heart transplantation
late rejection of graft
regulatory T cell
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
11
2020
accepted:
06
01
2021
entrez:
11
3
2021
pubmed:
12
3
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Little evidence has been presented about the association between previous atopic/allergic disease and graft rejection after solid organ transplantation. Thus, we present a case wherein acute cellular rejection (ACR) after heart transplantation (HTx) was noted along with exacerbation of atopic disease. A 32-year-old man was admitted at our hospital for regular monitoring of graft rejection. He had undergone heart transplant 3 years prior due to dilated cardiomyopathy. Echocardiogram revealed good biventricular function, and no abnormal findings were found in blood sampling tests. However, biopsy showed moderate ACR [Grade 2R(ISHLT 2004)/3A(ISHLT 1990)], which required twice-repeated steroid pulses with intensified immunosuppression. Meanwhile, his atopic dermatitis, which was diagnosed before having heart failure, was getting worse for the past 6 months. The exacerbation of atopic dermatitis was presumed to be related to the development of the intractable cellular rejection. This case suggested the association of atopic disease and graft rejection after HTx. We examined 76 patients from a cohort of previous studies who underwent HTx at our hospital, which suggested that patients with atopic/allergic disorders such as atopic dermatitis and asthma tended to have a significantly higher frequency of moderate rejection than non-allergic patients. (p = 0.012; Fisher's exact test). Our case also suggests that exacerbation of atopic dermatitis might cause graft rejection of the transplanted organ, so that it is important to carefully evaluate the risk of graft rejection if there is a previous history of atopic/allergic disease.
Sections du résumé
Background
Little evidence has been presented about the association between previous atopic/allergic disease and graft rejection after solid organ transplantation. Thus, we present a case wherein acute cellular rejection (ACR) after heart transplantation (HTx) was noted along with exacerbation of atopic disease.
Case Summary
A 32-year-old man was admitted at our hospital for regular monitoring of graft rejection. He had undergone heart transplant 3 years prior due to dilated cardiomyopathy. Echocardiogram revealed good biventricular function, and no abnormal findings were found in blood sampling tests. However, biopsy showed moderate ACR [Grade 2R(ISHLT 2004)/3A(ISHLT 1990)], which required twice-repeated steroid pulses with intensified immunosuppression. Meanwhile, his atopic dermatitis, which was diagnosed before having heart failure, was getting worse for the past 6 months. The exacerbation of atopic dermatitis was presumed to be related to the development of the intractable cellular rejection.
Discussion
This case suggested the association of atopic disease and graft rejection after HTx. We examined 76 patients from a cohort of previous studies who underwent HTx at our hospital, which suggested that patients with atopic/allergic disorders such as atopic dermatitis and asthma tended to have a significantly higher frequency of moderate rejection than non-allergic patients. (p = 0.012; Fisher's exact test). Our case also suggests that exacerbation of atopic dermatitis might cause graft rejection of the transplanted organ, so that it is important to carefully evaluate the risk of graft rejection if there is a previous history of atopic/allergic disease.
Identifiants
pubmed: 33692803
doi: 10.3389/fimmu.2021.630051
pmc: PMC7937951
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
630051Informations de copyright
Copyright © 2021 Kakuda, Amiya, Hatano, Maki, Bujo, Tsuji, Narita, Fujita, Ishida, Ono and Komuro.
Déclaration de conflit d'intérêts
EA and MH belong to the Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, which is endowed by Actelion Pharmaceuticals Japan Ltd., Otsuka Pharmaceutical, NIPRO CORPORATION, Terumo Corp., Senko Medical Instrument Mfg., Century Medical Inc., Kinetic Concepts Inc., and St. Jude Medical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2010 Jun 1;184(11):6076-83
pubmed: 20410484
Pediatr Transplant. 2006 May;10(3):380-3
pubmed: 16677366
Eur J Immunol. 2000 May;30(5):1290-6
pubmed: 10820374
Trends Immunol. 2001 May;22(5):247-51
pubmed: 11323281
Nat Med. 2008 Jan;14(1):88-92
pubmed: 18066074
Arch Dermatol. 1994 May;130(5):584-8
pubmed: 8179340
Transplantation. 2009 Apr 27;87(8):1191-200
pubmed: 19384166
Cells. 2020 Nov 20;9(11):
pubmed: 33233857
Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):573-4
pubmed: 18925409
Am J Transplant. 2013 May;13(5):1181-92
pubmed: 23489547
Am J Transplant. 2009 May;9(5):1017-26
pubmed: 19422331
Allergy Asthma Proc. 2006 Nov-Dec;27(6):451-5
pubmed: 17176778
JACC Heart Fail. 2017 Dec;5(12):857-868
pubmed: 29191293
Heart Vessels. 2021 Apr;36(4):499-508
pubmed: 33140148
J Pediatr. 2018 May;196:154-160.e2
pubmed: 29395171
Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):246-9
pubmed: 16394432
Int J Mol Sci. 2020 Oct 11;21(20):
pubmed: 33050549